Novartis escapes Gilenya kickback suit on lack of evidence by Kyle Blankenship Wednesday, March 25, 2020 Amid federal kickback charges, Novartis escaped a yearslong whistleblower lawsuit alleging it paid doctors to boost scripts of MS blockbuster Gilenya.
Merck KGaA's Mavenclad stakes its claim in competitive MS market by Kyle Blankenship Thursday, March 5, 2020 Competing with multiple blockbusters in multiple sclerosis, Merck KGaA's Mavenclad is making a name for itself with skyrocketing sales.
Ocrevus, Hemlibra offset Roche's biosim loss by Angus Liu Thursday, January 30, 2020 Roche Pharmaceuticals chief Bill Anderson played down gene therapy's near-term threat to Hemlibra, arguing hemophilia A patients are "well-served."
Which new MS drug do doctors like best? You might be surprised by Angus Liu Tuesday, November 19, 2019 A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.
Merck KGaA's MS launch Mavenclad offsets Rebif sales shortfall by Angus Liu Thursday, November 14, 2019 Mavenclad helped Merck KGaA's neuroscience portfolio grow 2.3% in the third quarter, even in the face of Rebif's 15% year-over-year sales decline.
Roche aims its first Ocrevus commercials at millennials by Beth Snyder Bulik Wednesday, October 30, 2019 Genentech has launched its first consumer campaign for multiple sclerosis drug Ocrevus, with emphasis on a particular cohort of patients: millennials.
Roche limits biosim damage to cancer blockbusters by Angus Liu Wednesday, October 16, 2019 Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact."
Biosimilars will leave a $10B gap in Roche's sales: exec by Angus Liu Tuesday, September 17, 2019 Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.
Roche's Ocrevus, given early, cuts wheelchair risk by 42%: study by Carly Helfand Friday, September 13, 2019 Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.
